These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

296 related items for PubMed ID: 7597041

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy.
    Ehsan A, Mann MJ, Dell'Acqua G, Dzau VJ.
    J Thorac Cardiovasc Surg; 2001 Apr; 121(4):714-22. PubMed ID: 11279413
    [Abstract] [Full Text] [Related]

  • 5. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia.
    Morishita R, Gibbons GH, Ellison KE, Nakajima M, Zhang L, Kaneda Y, Ogihara T, Dzau VJ.
    Proc Natl Acad Sci U S A; 1993 Sep 15; 90(18):8474-8. PubMed ID: 8104336
    [Abstract] [Full Text] [Related]

  • 6. Novel E2F decoy oligodeoxynucleotides inhibit in vitro vascular smooth muscle cell proliferation and in vivo neointimal hyperplasia.
    Ahn JD, Morishita R, Kaneda Y, Kim HS, Chang YC, Lee KU, Park JY, Lee HW, Kim YH, Lee IK.
    Gene Ther; 2002 Dec 15; 9(24):1682-92. PubMed ID: 12457282
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of mesangial cell proliferation by E2F decoy oligodeoxynucleotide in vitro and in vivo.
    Maeshima Y, Kashihara N, Yasuda T, Sugiyama H, Sekikawa T, Okamoto K, Kanao K, Watanabe Y, Kanwar YS, Makino H.
    J Clin Invest; 1998 Jun 01; 101(11):2589-97. PubMed ID: 9616230
    [Abstract] [Full Text] [Related]

  • 8. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial.
    Mann MJ, Whittemore AD, Donaldson MC, Belkin M, Conte MS, Polak JF, Orav EJ, Ehsan A, Dell'Acqua G, Dzau VJ.
    Lancet; 1999 Oct 30; 354(9189):1493-8. PubMed ID: 10551494
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. E2F decoy oligodeoxynucleotides effectively inhibit growth of human tumor cells.
    Ahn JD, Kim CH, Magae J, Kim YH, Kim HJ, Park KK, Hong S, Park KG, Lee IK, Chang YC.
    Biochem Biophys Res Commun; 2003 Oct 31; 310(4):1048-53. PubMed ID: 14559221
    [Abstract] [Full Text] [Related]

  • 12. Blocking the transcription factor E2F/DP by dominant-negative mutants in a normal breast epithelial cell line efficiently inhibits apoptosis and induces tumor growth in SCID mice.
    Bargou RC, Wagener C, Bommert K, Arnold W, Daniel PT, Mapara MY, Grinstein E, Royer HD, Dörken B.
    J Exp Med; 1996 Mar 01; 183(3):1205-13. PubMed ID: 8642262
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Local delivery of E2F decoy oligodeoxynucleotides using ultrasound with microbubble agent (Optison) inhibits intimal hyperplasia after balloon injury in rat carotid artery model.
    Hashiya N, Aoki M, Tachibana K, Taniyama Y, Yamasaki K, Hiraoka K, Makino H, Yasufumi K, Ogihara T, Morishita R.
    Biochem Biophys Res Commun; 2004 Apr 30; 317(2):508-14. PubMed ID: 15063786
    [Abstract] [Full Text] [Related]

  • 15. Suppression of proliferative cholangitis by E2F decoy oligodeoxynucleotide.
    Yoshida M, Yamamoto N, Nitta T, Uehara T, Terao R, Hatano E, Iimuro Y, Yamaoka Y.
    J Surg Res; 2002 Feb 30; 102(2):95-101. PubMed ID: 11796004
    [Abstract] [Full Text] [Related]

  • 16. E2F-dependent regulation of human MYC: trans-activation by cyclins D1 and A overrides tumour suppressor protein functions.
    Oswald F, Lovec H, Möröy T, Lipp M.
    Oncogene; 1994 Jul 30; 9(7):2029-36. PubMed ID: 8208548
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Dual control of myc expression through a single DNA binding site targeted by ets family proteins and E2F-1.
    Roussel MF, Davis JN, Cleveland JL, Ghysdael J, Hiebert SW.
    Oncogene; 1994 Feb 30; 9(2):405-15. PubMed ID: 8290253
    [Abstract] [Full Text] [Related]

  • 20. Growth inhibition of cultured human Tenon's fibroblastic cells by targeting the E2F transcription factor.
    Akimoto M, Hangai M, Okazaki K, Kogishi J, Honda Y, Kaneda Y.
    Exp Eye Res; 1998 Oct 30; 67(4):395-401. PubMed ID: 9820786
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.